Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Both cases were managed effectively with increased supplementation of calcium carbonate (1,200 mg/day) and calcitriol (0.5 µg/day) prior to the second denosumab administration.

Source: Denosumab-relevant adverse events. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Open-label reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This was a single-center, open-label, single-arm study designed to evaluate the effects of denosumab treatment in pediatric FD/MAS patients.

Source: Methods.

Patients aged 18 years or younger were recruited from the Department of Endocrinology at Peking Union Medical College Hospital (PUMCH).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Denosumab in pediatric patients with fibrous dysplasia/McCune-Albright syndrome: a single-center, open-labeled study

Study design awaiting verification · Frontiers in Endocrinology · 2026

Original publication title

Denosumab in pediatric patients with fibrous dysplasia/McCune-Albright syndrome: a single-center, open-labeled study

Quanshi Ouyang; Ruizhi Jiajue; Ruotong Zhou; Wenting Qi; Xiang Li; Lijia Cui; Yue Chi; Qianqian Pang; Yiyi Gong; Wei Liu; Yan Jiang; Ou Wang; Mei Li; Xiaoping Xing; Weibo Xia

Copyright © 2026 Ouyang, Jiajue, Zhou, Qi, Li, Cui, Chi, Pang, Gong, Liu, Jiang, Wang, Li, Xing and Xia.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Denosumab appears to be effective in pediatric FD/MAS patients, however safety concerns remain. Comprehensive pre-treatment evaluation and close monitoring throughout the treatment course are essential. Further prospective studies and randomized controlled trials are needed to determine optimal dosing strategies and establish long-term safety in this population.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Investigate the efficacy and safety of denosumab in pediatric FD/MAS population.

Source: Objective

Abstract: Context

Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS) is a rare skeletal disorder frequently manifesting in childhood, often leading to progressive bone lesions, pain and functional impairment. Denosumab as a monoclonal antibody targeting RANKL has emerged as a potential therapeutic option, while its safety and efficacy in pediatric population remains poorly defined.

Source: Context

Abstract: Design

12-month single-arm study.

Source: Design

Abstract: Setting

Single center study at Peking Union Medical College Hospital.

Source: Setting

Abstract: Patients

FD/MAS patients under 18.

Source: Patients

Abstract: Interventions

Denosumab 1mg/kg with a maximum dosage of 60mg every 3 months for 12-month follow-up.

Source: Interventions

Abstract: Main outcome measures

FD-related bone pain, bone turnover markers, 99mTc-MDP bone scintigraphy, bone mineral density.

Source: Main outcome measures

Abstract: Results

In 5 pediatric FD/MAS patients treated with denosumab, significant clinical improvements were observed, including alleviation of FD-associated bone pain, reductions in bone turnover markers, and regression of FD lesions. Alkaline phosphatase levels dropped to an average of 41.8% of baseline, accompanied by concurrent reductions in C-terminal telopeptide and type 1 N-terminal pro-peptide levels. Adverse events particularly hypercalcemia following treatment cessation occurred in 2 of the 5 patients, indicating a relatively high incidence of rebound hypercalcemia and highlighting the need for careful monitoring and cautious use of denosumab in pediatric patients.

Source: Results

Abstract: Conclusions

Denosumab appears to be effective in pediatric FD/MAS patients, however safety concerns remain. Comprehensive pre-treatment evaluation and close monitoring throughout the treatment course are essential. Further prospective studies and randomized controlled trials are needed to determine optimal dosing strategies and establish long-term safety in this population.

Source: Conclusions
Authors’ abstract

Context

Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS) is a rare skeletal disorder frequently manifesting in childhood, often leading to progressive bone lesions, pain and functional impairment. Denosumab as a monoclonal antibody targeting RANKL has emerged as a potential therapeutic option, while its safety and efficacy in pediatric population remains poorly defined.

Objective

Investigate the efficacy and safety of denosumab in pediatric FD/MAS population.

Design

12-month single-arm study.

Setting

Single center study at Peking Union Medical College Hospital.

Patients

FD/MAS patients under 18.

Interventions

Denosumab 1mg/kg with a maximum dosage of 60mg every 3 months for 12-month follow-up.

Main outcome measures

FD-related bone pain, bone turnover markers, 99mTc-MDP bone scintigraphy, bone mineral density.

Results

In 5 pediatric FD/MAS patients treated with denosumab, significant clinical improvements were observed, including alleviation of FD-associated bone pain, reductions in bone turnover markers, and regression of FD lesions. Alkaline phosphatase levels dropped to an average of 41.8% of baseline, accompanied by concurrent reductions in C-terminal telopeptide and type 1 N-terminal pro-peptide levels. Adverse events particularly hypercalcemia following treatment cessation occurred in 2 of the 5 patients, indicating a relatively high incidence of rebound hypercalcemia and highlighting the need for careful monitoring and cautious use of denosumab in pediatric patients.

Conclusions

Denosumab appears to be effective in pediatric FD/MAS patients, however safety concerns remain. Comprehensive pre-treatment evaluation and close monitoring throughout the treatment course are essential. Further prospective studies and randomized controlled trials are needed to determine optimal dosing strategies and establish long-term safety in this population.

Publication and source details

Original title: Denosumab in pediatric patients with fibrous dysplasia/McCune-Albright syndrome: a single-center, open-labeled study

Quanshi Ouyang; Ruizhi Jiajue; Ruotong Zhou; Wenting Qi; Xiang Li; Lijia Cui; Yue Chi; Qianqian Pang; Yiyi Gong; Wei Liu; Yan Jiang; Ou Wang; Mei Li; Xiaoping Xing; Weibo Xia

Frontiers in Endocrinology · 2026

* Correspondence: Weibo Xia, xiaweibo8301@163.com

†These authors share first authorship

‡ORCID: Weibo Xia, orcid.org/0000-0001-7768-5536

Copyright © 2026 Ouyang, Jiajue, Zhou, Qi, Li, Cui, Chi, Pang, Gong, Liu, Jiang, Wang, Li, Xing and Xia.2026Ouyang, Jiajue, Zhou, Qi, Li, Cui, Chi, Pang, Gong, Liu, Jiang, Wang, Li, Xing and Xiahttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. The research is funded by: Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0532204); National Key R&D Program of China (2021YFC2501700); CAMS Innovation Fund for Medical Sciences (CIFMS) 2021-I2M-1-002; National High Level Hospital Clinical Research Funding (2022-PUMCH-D-006); the National Natural Science Foundation of China No.82270938, No.81970757; the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2023-PT320-10).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:00:18.431858+00:00

DOI: 10.3389/fendo.2026.1762370 · PMC12956703